another paper published a couple of days ago using anteobind
"Screening was carried out in two phases, with a multiplex bead-based assay in the first subset (until September 2021) and with targeted assays for the second (until October 2022)."
"The first step in the established protocol was the creation of beads coupled to targeted antigens, as detailed previously32,33,34. Magnetic beads (MagPlex®, Luminex) were coupled with commercial, full-length target proteins by use of an AnteoTech activation kit (A-LMPAKMM-10)."
just some points from this paper and the many others published over the last couple of years.
- this paper is from Sweden. have had papers published from all over the world. there is no or very little revenue from these but they do validate Anteotech's anteobind technology. as well as gaining recognition.
this is just one paper published that used anteobind
- this paper was published 2 days ago, screening was happening in 2020-2022. since David took over it has been announced many times that anteotech will push anteobind into uni's. anteobindNXT was only launched 3 months ago. so there is most likely anteobind products in a lot of studies at the moment, moving the technology forward into potential markets and increasing brand recognition.
- "Magnetic beads (MagPlex®, Luminex) were coupled with commercial, full-length target proteins by use of an AnteoTech activation kit (A-LMPAKMM-10)."
just another paper using Anteobind products with magplex Luminex. the likelihood of a partnership with Luminex is something to watch
- lastly this is another paper using anteobind in comparing single assays versus a multiplex assay. a strength of anteobind being the ability to multiplex. again Anteotech is positioned strongly in a new growth area
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)